Vaginal Estrogen Cream: Uses, Safety, and How to Use It

• Vaginal estrogen cream restores thinning vaginal and urinary tissue after menopause, easing dryness, painful sex, and recurrent UTIs.
• It is not the same as systemic HRT. Standard doses release very little oestrogen into the bloodstream, so the risks are far lower.
• It works only while you use it. Most women apply daily for 1-2 weeks, then 2-3 times a week long term.
• It has the strongest evidence of any treatment for preventing recurrent UTIs in postmenopausal women.
• It is generally safe without added progestogen, and many breast cancer survivors can use it after discussion with their oncologist.
• It is widely underused in India for cultural and awareness reasons, not medical ones. Ask your doctor specifically about it.

Vaginal estrogen cream is a topical preparation containing oestrogen (usually conjugated estrogens, estradiol, or estriol) that you apply directly inside the vagina and around the vulva. The oestrogen is absorbed locally, where it rebuilds tissue thickness, restores lubrication and blood flow, and brings back the healthy acidic environment that protective lactobacilli need. Only a small amount enters your bloodstream.

This is the key difference from systemic hormone replacement therapy (HRT). Oral tablets, patches, and gels deliver oestrogen at doses high enough to act throughout the body. They treat hot flushes, night sweats, and mood changes and help protect bone, but they also carry the risks people associate with hormone therapy. If you are weighing whole-body treatment, our guide to HRT options and costs in India goes deeper into systemic hormone therapy.

Because vaginal estrogen at standard doses keeps blood oestrogen in the low postmenopausal range, it does not usually need a progestogen to protect the uterus, unlike systemic oestrogen in women with a uterus. It also sidesteps most of the concerns tied to systemic HRT, which is why guideline bodies treat it as a separate, lower-risk option.

It comes in several forms: creams applied with an applicator or fingertip, vaginal tablets or pessaries, and slow-release rings. In India, creams are by far the most commonly prescribed. When used correctly, all forms work similarly well.

It works while you use it, and the effects fade when you stop. Most women who benefit continue indefinitely at a maintenance dose, with periodic review by their doctor. This is different from systemic HRT, where treatment duration is often more limited and individualised.

Genitourinary syndrome of menopause (GSM) is the current medical term for what used to be called "vaginal atrophy" or "atrophic vaginitis". It captures the full picture: changes across the vulva, vagina, urethra, and bladder caused by falling oestrogen after menopause. The term was adopted in 2014 precisely because the older labels missed the urinary side of the problem.

GSM affects an estimated 50-80 percent of postmenopausal women, though many never report it. They may feel embarrassed, assume it is just ageing, or not know it can be treated. In India this undertreatment is even more common, because intimate symptoms are rarely discussed and many women stop seeing a gynaecologist after their reproductive years.

Symptoms fall into two groups. Vaginal symptoms include dryness, burning, itching, a change in discharge, painful sex (dyspareunia), light bleeding after sex from fragile tissue, and reduced desire because of discomfort. Urinary symptoms include frequency, urgency, burning when you pee, leakage, and repeated urinary infections.

On examination, a doctor may see pale, thin vaginal walls, loss of the normal folds, reduced moisture, a narrowed opening, and tissue that bleeds easily on contact. Some women have many of these signs with few symptoms; others have severe symptoms with modest findings.

Unlike hot flushes, which fade over time, GSM is progressive without treatment and tends to worsen through the 60s and beyond. Early treatment can prevent much of that decline, but starting late still helps. No woman should be told this is simply something to live with.

Vaginal estrogen is mainly for GSM and its related problems: vaginal dryness, painful sex from atrophy, burning or itching, recurrent urinary tract infections linked to postmenopausal thinning, atrophy-related urinary urgency or frequency, and spotting after sex from fragile tissue. The evidence is strongest for dryness, painful sex, and recurrent UTI prevention.

Postmenopausal women are the main group. There is no upper age limit. Treatment is guided by symptoms, or sometimes by atrophy found on examination in a woman with recurrent UTIs. Our deeper look at vaginal dryness causes and treatment in India covers the wider picture.

Surgical menopause, after both ovaries are removed at any age, can bring on severe, rapid GSM. Vaginal estrogen suits these women, often alongside systemic HRT for hot flushes and bone health.

Younger women with premature ovarian insufficiency, where the ovaries fail before 40, may also need oestrogen replacement. They are usually managed with combined systemic and vaginal treatment and should see a gynaecologist familiar with the condition.

Women on aromatase inhibitors after breast cancer often develop marked GSM because these drugs deeply suppress oestrogen. Vaginal estrogen here needs individualised oncologist input. Guidance has shifted toward allowing low-dose vaginal estrogen in selected survivors with severe symptoms when non-hormonal measures fail.

Vaginal estrogen is generally not used in premenopausal women with normal oestrogen, in anyone with unexplained vaginal bleeding that has not yet been investigated, in women with active or recent breast or endometrial cancer without specialist input, or where there is known allergy to an ingredient. These cautions are mostly relative, not absolute, and should be talked through with a clinician.

Several preparations are available by prescription in India. The commonest are conjugated estrogens vaginal cream (Premarin Vaginal Cream), estradiol vaginal cream, estradiol vaginal tablets or pessaries, and estriol preparations. Availability varies by city and pharmacy.

Premarin Vaginal Cream contains 0.625 mg conjugated estrogens per gram and comes with an applicator. A common regimen is a small applicator dose intravaginally daily for 1-2 weeks to restore the tissue, then twice-weekly maintenance. The lower end (about 0.5 g twice weekly) is often enough for maintenance and keeps systemic absorption minimal. A tube typically costs around Rs 1,500-3,500 and lasts several months at maintenance dosing.

Generic estradiol vaginal creams are also available, usually at lower cost, with similar application schedules. Vaginal tablets or pessaries are inserted with a small applicator and may suit women who find creams messy or want something more discreet.

Estriol preparations use a weaker oestrogen with even less systemic absorption and are well established in Europe; availability in India varies. Slow-release vaginal rings (such as Estring), convenient because one ring lasts about three months, are widely used abroad but have limited availability here.

On cost: because a single tube lasts months at maintenance dosing, the per-month spend is modest, often roughly Rs 200-400. Generics can be cheaper, and government and teaching hospitals may offer lower-cost or formulary access. Since long-term use is the norm, factor in the cost over time when you and your doctor choose a formulation.

Most creams come with a marked applicator. Fill it to the prescribed level, insert it gently into the vagina, and press the plunger to release the cream. If the dose is small or the applicator is awkward, you can apply with a clean finger.

Bedtime is usually best, so the cream stays in contact with the tissue overnight rather than leaking out during the day. A little leakage in the morning is normal; a panty liner helps. Wait at least 30-60 minutes after applying before sex, to avoid transferring cream to your partner.

Wash your hands before and after. Rinse a reusable applicator in warm soapy water and let it air dry; discard single-use applicators.

A small amount can also be applied externally to the vulva and around the opening of the urethra if those areas are affected. This is done with a clean fingertip and can be especially helpful for urinary symptoms such as urgency, frequency, and recurrent UTIs.

The usual pattern is a loading phase of daily use for 1-2 weeks, then maintenance 2-3 times a week. Milder cases may manage with once weekly; severe atrophy may need more at first. Adjust with your doctor's guidance based on how your symptoms respond.

Most women notice improvement within 2-4 weeks, with continued gains over 2-3 months as the tissue rebuilds, pH normalises, and lactobacilli return. If nothing has changed by 4-6 weeks, talk to your doctor; you may need a higher dose, a correction in technique, longer treatment, or review of the diagnosis.

A few special situations: keep using it through any menstrual bleeding if you still have periods; treat an active yeast or bacterial infection first and ask whether to pause; restart after vaginal surgery only once healed and your surgeon agrees; and you can usually continue it during an antibiotic course for a UTI.

At standard doses the safety profile is reassuring for most postmenopausal women, because so little oestrogen reaches the bloodstream. Large studies have not shown meaningful increases in heart disease, stroke, blood clots, or breast cancer with low-dose vaginal estrogen. Blood oestradiol on maintenance dosing typically stays in the low postmenopausal range.

Endometrial safety has been studied closely. Standard-dose vaginal estrogen has not been shown to cause clinically significant thickening of the womb lining or cancer in postmenopausal women, which is why a progestogen is not routinely added. Surveillance may be considered for higher long-term doses or added risk factors. Any new vaginal bleeding while using it should always be checked.

Breast cancer survivors are a special case. The old blanket caution has softened. Major bodies now accept that for survivors with severe GSM that has not responded to non-hormonal measures, low-dose vaginal estrogen can be considered after an individualised discussion with the oncologist, particularly for women on tamoxifen rather than aromatase inhibitors. If you are managing your own breast health, see our guide to breast cancer detection and treatment.

Other situations that call for an individual decision include a history of endometrial or other oestrogen-sensitive cancer, previous blood clots, and active liver disease. Most of these are relative cautions to discuss, not automatic bans.

Side effects are usually mild and local: a little discharge or moisture (often a sign it is working), occasional irritation, brief spotting early on, and rarely a reaction to a cream ingredient. Whole-body side effects are uncommon at standard doses.

Long-term use is expected, because the underlying oestrogen deficiency persists. Symptoms tend to return within months of stopping, so most women continue with maintenance dosing and periodic review. There is no fixed time limit on treatment.

One of the strongest reasons to use vaginal estrogen is preventing recurrent UTIs after menopause. Randomised trials have shown it substantially reduces recurrences, and urology guidelines specifically endorse it as an effective preventive option in postmenopausal women.

The mechanism is well understood. Oestrogen loss thins the tissue, drives away protective lactobacilli, and pushes vaginal pH up from the healthy 3.5-4.5 range, letting E. coli and other uropathogens take hold. Vaginal estrogen reverses all of this, restoring tissue, lactobacilli, and a protective pH.

Compared with long-term preventive antibiotics, it fixes the underlying cause rather than just suppressing infections, does not add to antibiotic resistance, and brings extra relief for vaginal and urinary symptoms. Costs are broadly comparable over time.

For Indian postmenopausal women with recurrent UTIs, vaginal estrogen deserves to be a first-line preventive option. If symptoms have ever dragged on after treatment, our explainer on whether UTI symptoms can linger after antibiotics is worth a read.

It pairs well with everyday measures: staying well hydrated, not holding urine, and peeing after sex. Several simple rules can help prevent cystitis too. Some women add D-mannose 2 g daily or try cranberry products, though the evidence for cranberry is mixed; these are complementary to, not replacements for, treating the atrophy itself.

Painful intercourse is one of the most common and distressing GSM symptoms. Atrophic tissue loses elasticity and lubrication and tolerates friction poorly, so sex can hurt enough that women avoid it. Many postmenopausal Indian women endure this silently for years, assuming it is just age. Our dedicated piece on painful sex after menopause explores this in depth.

Vaginal estrogen substantially improves atrophy-related painful sex. Within 2-4 weeks women usually notice better natural lubrication and less burning; over 2-3 months elasticity improves and the opening regains some capacity. Severe atrophy may take longer to fully recover.

It is more effective than lubricants and moisturisers alone for moderate-to-severe atrophy, but the three work well together. A lubricant used during sex reduces friction in the moment, while a hyaluronic-acid vaginal moisturiser keeps tissue comfortable between encounters.

For severe narrowing or a tight, guarded pelvic floor built up over years of pain, pelvic floor exercises and rehabilitation and graded use of vaginal dilators help reopen and relax the vagina. These services are expanding in major Indian cities.

Desire often recovers once sex stops hurting. If low libido lingers, our guide to changes in libido around menopause may help. Open conversation matters too, and easing avoidance patterns that persist even after the physical problem is treated often makes the biggest difference.

Restored, comfortable sex is a realistic goal for most women with GSM-related pain. It is not a permanent feature of ageing.

If you cannot or prefer not to use vaginal estrogen, several non-hormonal options give partial relief, and they also work as add-ons for extra comfort.

Vaginal moisturisers, used regularly every 2-3 days, provide ongoing moisture. Hyaluronic-acid based products are popular and typically cost around Rs 300-800 per pack. They lubricate and soothe but do not rebuild tissue or restore pH the way oestrogen does, and need weeks of regular use for noticeable benefit.

Lubricants are used at the time of sex to cut friction. Water-based options are cheap and widely available; silicone-based ones last longer but cost more. Oil-based products can weaken latex condoms and irritate, so are generally avoided. Lubricants ease intercourse but do not treat the underlying atrophy.

Ospemifene, an oral selective oestrogen receptor modulator for painful sex, and vaginal DHEA (prasterone) inserts both act on vaginal tissue and may suit some women who avoid oestrogen, but availability in India is limited.

So-called vaginal "rejuvenation" using laser or radiofrequency has been heavily marketed, but the evidence for GSM is weak, regulators have warned about potential harm, and major medical societies do not endorse it as standard care. Be cautious of commercial claims.

Combinations often work best. A practical regimen might be vaginal estrogen 2-3 times a week, a hyaluronic-acid moisturiser on the in-between days, and a water-based lubricant during sex, a layered approach that can transform daily comfort and intimacy.

Despite strong evidence and a good safety record, vaginal estrogen is underused in India, mostly for non-medical reasons.

The biggest barrier is reluctance to raise intimate symptoms. Many women, especially older ones, find it hard to mention dryness, painful sex, or urinary problems, or assume discomfort is inevitable. Doctors can help by asking proactively rather than waiting for patients to bring it up, and women can prepare for that conversation with our guide on talking to your doctor about vaginal pain.

Awareness among some clinicians is also uneven. Menopause-focused gynaecologists in larger cities know GSM well, but it is sometimes overlooked elsewhere. Raising the topic of vaginal estrogen explicitly often leads to appropriate care.

General fear of "hormones" after the publicity around systemic HRT also puts women off. Separating vaginal estrogen, with its minimal systemic absorption, from whole-body HRT removes a lot of unnecessary worry, and understanding the wider menopause picture helps you see where each treatment fits.

Access is uneven because many women stop seeing a gynaecologist after their reproductive years. Continuing annual gynaecology visits throughout life, and raising GSM specifically, keeps these options open. Telemedicine consultations can fill gaps where local menopause care is limited.

Family and partner understanding matters too, since many health decisions are shared. Accurate information about why these symptoms happen, and what helps, makes it easier for women to get the treatment they need without resistance.

See a doctor before starting, and during treatment, in these situations:

Most importantly, see a doctor promptly for any new or unexplained vaginal bleeding after menopause. This must be investigated before assuming it is harmless, even if you are using vaginal estrogen.

Also seek care if symptoms are severe or not improving after 4-6 weeks of correct use, if you have repeated UTIs, fever, back or flank pain, or blood in your urine, or if intercourse remains painful despite treatment.

• The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society (NAMS/The Menopause Society)
• ACOG: Treatment of Urogenital Symptoms in Individuals With a History of Estrogen-dependent Breast Cancer (Committee Opinion)
• NICE Guideline NG23: Menopause - diagnosis and management
• American Urological Association: Recurrent Uncomplicated Urinary Tract Infections in Women - AUA/CUA/SUFU Guideline
• NHS: Menopause - treatment (vaginal oestrogen and lubricants)